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Abstract 
In the field of medical diagnosis magnetic resonance imaging (MRI) has become a 
powerful tool. High spatial resolution and the capacity of differentiating soft tissue 
made MRI the most widespread imaging modality in clinical diagnosis. This technique 
is non invasive and therefore provides biomedical spectroscopy and spatial 
information without destroying the investigated sample. To increase the effectiveness 
of MRI and therefore enhance contrast between tissues paramagnetic contrast 
agents (CA) are applied. Though, these low molecular CA suffer from quick diffusion 
into the interstitium and rapid renal clearance. To overcome the mentioned limitations 
CA are coupled to nanosized carriers. This method promises prolonged intravascular 
retention leading to an increase in time, suitable for MRI measurements and due to 
prevented diffusion, an improved contrast. 
In effort to develop improved nanosized MRI CA, this thesis focuses on the 
evaluation of different strategies for the conjugation of a bifunctional chelating ligand 
to a nanosized carrier protein. The methods developed in this work were evaluated 
according to the amount of attached bifunctional chelators, the shape and size 
dimension of the resulting particles and finally, their impact on magnetic relaxation. 
In order to accumulate nanoshaped CA in the vasculature and visualize pathogenic 
alteration of blood vessels, the prepared CA were conjugated to an endothelial cell 
targeting lectin. These crosslinked nanoparticles were prepared in different sizes and 
lastly, MRI experiments were performed to determine relaxation. 
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Zusammenfassung 
Magnetic Resonance Imaging (MRI) zählt heute zu den wichtigsten bildgebenden 
Verfahren in der medizinischen Diagnostik. Hohe räumliche Auflösung und die 
Fähigkeit zwischen verschieden Gewebearten zu unterscheiden, haben erheblich zur 
Verbreitung der Magnetresonanztomographie als Diagnoseinstrument beigetragen. 
Mit Hilfe dieser nicht invasiven Technik ist es möglich, exakte, biomedizinische 
Informationen zu erhalten, ohne die zu untersuchende Probe zu schädigen. Um die 
Leistung der Magnetresonanztomographie zu verbessern und die erhaltenen Signale 
zu verstärken, werden häufig paramagnetische Kontrastmittel eingesetzt. Diese 
niedermolekularen Substanzen weisen jedoch einen entscheidenden Nachteil auf: 
sie diffundieren rasch durch Poren in Blutgefäßen in angrenzendes Gewebe und 
werden schnell durch die Niere abgebaut und ausgeschieden. Eine 
vielversprechende Möglichkeit die Verweildauer in Blutgefäßen zu erhöhen ist, diese 
Kontrastmedien an makromolekulare Trägersubstanzen zu binden. Dadurch wird ein 
zu rasches Diffundieren verhindert und ein verlängerter Zeitrahmen für MRI 
Messungen, der verbesserte Abbildungen ermöglicht, steht zur Verfügung. 
Im Bestreben, verbesserte Kontrastmittel im Nanometermaßstab zu entwickeln, zielt 
die vorliegende Arbeit auf die Entwicklung neuer Kopplungstechniken zwischen 
bifunktionellen Komplexbildnern und Trägerproteinen ab. Die daraus resultierenden 
modifizierten Proteine wurden auf den Gehalt anhängender Liganden, Größe und 
Struktur getestet. Anschließend gaben MRI Messungen über den Einfluss auf die 
Relaxivität, Auskunft. 
Zusätzlich wurden diese nanopartikuären Kontrastmedien mit Lektinen gekoppelt, die 
an Endothelzellen binden. Damit soll eine noch längere Verweilzeit in Blutgefäßen 
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gewährleistet werden, was die Diagnose von krankhaften Veränderungen verbessert. 
Diese Lektinkonjugate wurden mithilfe unterschiedlicher Methoden in verschiedenen 
Größen hergestellt und ebenfalls ihr Einfluss auf das Relaxivitätsverhalten getestet. 
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Abbreviations 
BFCA bifunctional contrast agent 
Bn benzyl 
BOPTA 3-benzyloxy-2-[(2-{[2-(biscarboxymethyl-
amino)ethyl]carboxymethylamino}ethyl)carboxymethylamino]- 
propionic acid 
BT-DO3A 1,4,7,10-tetraazacyclododecane-1-(2,3-dihydroxy-1-
hydroxymethylpropyl)-4,7,10-trisacetic acid 
CA contrast agent 
CT computed tomography 
Da Dalton 
DOTA 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid 
DTPA diethylenetriaminepentaacetic acid 
DTPA-BMA DTPA-bismethylamide 
DTPA-BMEA DTPA-bismethoxyethylenamide 
EOB-DTPA {[2-(biscarboxymethylamino)-3-(4-ethoxyphenyl)propyl]-[2-
(biscarboxymethylamino)ethyl]amino}acetic acid 
ESI-MS electrospray ionisation mass spectrometry 
Fmoc Fluorenylmethoxycarbonyl 
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HP-DO3A 1,4,7,10-tetraazacyclododecane-1-hydroxypropyl-4,7,10-
trisacetic acid 
HSA human serum albumin 
ICP-MS inductively coupled plasma mass spectrometry 
LEA Lycopersicon esculentum agglutinin 
MRI magnetic resonance imaging 
NMR nuclear magnetic resonance 
PET positron emission tomography 
pH pondus Hydrogenii 
SAXS small angle X-ray scattering 
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Introduction 
Introduction 
The application of magnetic resonance imaging for the visualization of internal 
structures in humans was first described in 1977 (1). In the field of medical diagnosis 
and biomedical research magnetic resonance imaging (MRI) has become a versatile 
technique. High spatial resolution and the capacity of differentiating soft tissue made 
MRI the most widespread imaging modality in clinical diagnosis. This imaging 
technique is non invasive and therefore provides biomedical spectroscopy and spatial 
information without destroying the investigated sample. Generation of images by this 
method is based on the principles of nuclear magnetic resonance (NMR) – a well 
known tool for the characterization of chemical substances. The resonance of water 
protons combined with computational tools enables three dimensional visualization of 
the investigated biological structure. Beside MRI, several other medical imaging 
modalities are currently applied.  
 
Radiography: 
Radiography was the first and for a long period of time the only imaging modality 
available. Radiographs are generated by transmission of X-rays through the patient 
to a silver impregnated film. The contrast is produced by different scattering effects 
based on distinct tissue densities when X-rays pass the body and hit the impregnated 
film. It is still the first study ordered in evaluation of the lungs, heart and skeleton 
because of its wide availability, speed and relative low cost. A risk to health poses the 
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use of ionizing radiation. X-rays have the potential of causing genetic damage and 
cancer. 
 
Fluoroscopy: 
Fluoroscopy is used to obtain moving real time images of internal structures by 
employment of a fluoroscope. In the fluoroscope the patient is placed between an X-
ray source and a fluorescent screen coupled to an X-ray image intensifier. Swallowed 
or injected contrast enhancing agents are used to investigate anatomy and 
functioning of the blood vessels, the genitourinary or the gastrointestinal tract. 
Radiocontrast agents like barium sulfate or iodine in different modifications strongly 
absorb or scatter X-ray radiation, and in conjunction with the real-time imaging 
provide insight to internal dynamic processes. Due to the use of X-ray, fluoroscopy 
poses a high potential risk to patients. 
 
Computed Tomography (CT) 
In CT, X-rays and computing algorithms generate three dimensional images of the 
examined body. An X-ray source together with an X-ray detector in the opposite are 
placed in a short tubular apparatus rotating around a patient and produce computer 
generated cross-sectional images (tomogram) in high spatial resolution. CT scans of 
internal organs, bones, soft tissue and blood vessels provide greater clarity and 
reveal more details than regular X-ray exams. Iodine-based contrast agents are 
considered as industry standard for CT but additionally, gadolinium-containing 
contrast agents have been used in place of iodinated contrast agents for certain 
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applications. Again the involvement of ionizing radiation causes concerns about the 
potential health risk. CT exposes the patient to more radiation than a radiograph. 
 
Nuclear Medicine: 
Nuclear medicine involves the administration of radioactive tracers coupled to 
substances with affinity for certain body tissues. Generally, radioactive isotopes of 
gallium, iodine and thallium are used as tracers. Nuclear medicine does not provide 
high spatial resolution images but it enables insight in the physiological function of 
the examined tissue. Produced images can be combined with simultaneously taken 
CT scans to improve the diagnostic accuracy.  
A nuclear medicine technology using a radioactive biologically-active substance - 
most often fluorine-18 - is positron emission tomography (PET). Metabolically more 
active tissues like cancer concentrate the active fluorine-18 more than other tissues. 
The functional images provided by PET, displaying the spatial distribution of 
metabolic and biochemical processes, is often combined with high spatial resolution 
anatomical images from CT to increase precision of generated information. 
 
Ultrasound:  
Visualization of soft tissue structures in real time is provided by the utilization of 
ultrasound. This so called ultrasonography enables three dimensional imaging of fetal 
anatomic development as well as dynamic evaluation of the heart and major blood 
vessels. Limitations arise by the incapability to image through air (lungs) or bones. 
Compared to other diagnostic facilities the equipment for this technology is cheap 
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and is therefore one of the most widespread imaging modality in modern medicine. 
Ultrasonography does not use ionizing radiation and is hence, generally considered 
safe. Nevertheless, ultrasound enhances inflammatory response and it can heat soft 
tissue. 
 
Beside the already mentioned non invasiveness, MRI displays another important 
advantage compared to the imaging techniques described above which has highly 
contributed to its widespread use. It does not expose the patient to harmful ionizing 
radiation. Furthermore, MRI scans give the best soft tissue contrast of all the imaging 
modalities (2, 3, 4, 5). 
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Physical principles of MRI  
Absorption and emission of energy in the radio frequency range of the 
electromagnetic spectrum is the base of MRI. Produced images derive from spatial 
variations in the phase and frequency of the radio frequency energy being absorbed 
and emitted by the imaged object. The human body mostly consists of water. Nuclei 
of hydrogen protons have a quantum mechanical property – the nuclear spin angular 
momentum. This is a vector (I) and can be quantified with the use of the Plank 
constant h.  
)1(
2
+= IIhI
pi
 
For hydrogen the nuclear spin quantum number is ½. Placed in an external magnetic 
field (B0), the hydrogen spin will precess about B0 with the Larmor frequency (ω) in a 
discrete direction (Figure 1).  
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Figure 1 Precession of the magnetic moment µ about B0 with the Larmor frequency ω 
 
The spin of ½ enables two possible alignments corresponding to the energy level of 
the nucleus. Distribution of the spins between the two possible states is according to 
Boltzmann distribution, which is dependent on temperature T and the energy 
difference ∆E between the allowed states. The Boltzmann constant is represented by 
k.
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For hydrogen, the two energy states are N+1/2 spin ‘up’ (low energy) and N-1/2 spin 
‘down’ state (high energy). The Boltzmann distribution shows that at 37°C, the 
average body temperature, slightly more spins occupy the lower energy state 
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generating the net magnetization vector M. These excess spins are used for the 
generation of the signal. The energy difference between the high and low energy 
states is proportional to the strength of the externally applied magnetic field B0. The 
greater the strength of the external field, the greater the energy difference between 
the two spin states. 
A second radiofrequency pulse which is perpendicular to B0 can now be applied to 
generate field B1. This field causes spins to flip off the z-axis and turn the net 
magnetization towards the transverse plane (x and y axis) 
 
 
Figure 2 Application of a perpendicular radiofrequency pulse 
 
The precessing about the z-axis in a xy-plane generates a detectable field. After the 
pulse, the generated B1 ceases to exist and the nuclear spins return to their ground 
state. This process is called relaxation. The time required to return to the ground 
state is termed relaxation time. Relaxation time data of measured samples are used 
to produce the MR image. 
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Relaxation is considered in two parts: the recovery toward equilibrium alignment and 
the transverse decay. The return of the M alignment around the z-axis to equilibrium 
by a time constant is termed the spin-lattice relaxation T1. Duration of the return from 
transverse decay is described as spin-spin relaxation T2. These parameters provide 
MRI its power to distinguish between different tissues. T1 and T2 are properties of the 
water environment and thus of different tissue types. They differ between tissues due 
to the different physicochemical microenvironments of tissues like water mobility, the 
presence of microstructures, macromolecules and membranes (2, 3, 4). 
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Conrast agents in MRI 
Spatial resolution in MRI is high. However, the potential of this diagnostic modality 
can be improved by the introduction of contrast agents (CA). MRI contrast agents are 
a class of pharmaceuticals that enhance the image contrast between tissues in which 
the agent accumulates and other tissues. This provides better differentiability of 
normal and diseased tissue and shows the status of organ function or blood flow (6). 
Nowadays, more than 35% of clinical MRI examinations are performed with the use 
of CA (7).  
 
Types of CA 
Currently availably CA for magnetic resonance can be divided into two groups: T1 
agents and T2 agents. Generally, T1 agents increase the spin-lattice relaxation rate 
(1/T1) of hydrogen protons in tissue. This T1 lowering effect increases the signal 
intensity on T1 weighted images. T1 agents have very little impact on the spin-spin 
relaxation. Due to the increase of signal intensity T1 agents are called positive 
contrast agents. On the other hand, T2 agents largely influence the spin-spin 
relaxation rate (1/T2) by decrease of T2. This results in the decrease of signal 
intensity on T2 weighted images. Thus, these agents represent negative contrast 
agents (8) (Figure 3). 
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Figure 3. MRI scans of the brain. A and C are T1 weighted images; B and D are T2 weighted images. 
Picture taken from reference 9 with permission of the Centers for Disease Control and Prevention. 
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Due to their magnetic behavior, MRI CA can as well be described as 
superparamagnetic and paramagnetic agents. 
 
Superparamagnetic contrast agents  
Superparamagnetic contrast agents are water insoluble iron oxide crystals, usually 
based on magnetite (Fe3O4) or maghemite (γ-Fe2O3). Each iron oxide crystal consists 
of thousands of paramagnetic Fe ions (Fe2+ and Fe3+), and if the Fe ions are 
magnetically aligned within the crystal, the net magnetic moment of the particle 
greatly exceeds that of typical paramagnetic ions. This effect is referred to as 
superparamagnetism and is characterized by a large magnetic moment in the 
presence of an external magnetic field (10).  
Iron oxide CA are often coated by macromolecular materials including dextran, 
polysaccharide, chitosan, starch, albumin polystyrene and others. These contrast 
agents are commonly divided into three classes according to the mean total 
diameter. Below a size of 50 nm they are called ultra small superparamagnetic iron 
oxide (USPIO) particles. The term superparamagnetic iron oxide (SPIO) refers to 
particles where the mean diameter rises above 50 nm. And third, if the diameter is 
larger than 200 nm they are simply called large particles (6). Iron oxide agents do not 
leak into the interstitium and therefore they act as intravascular CA as long as the 
vessel endothelium is not altered by pathological processes.  
The relaxation mechanism of these CA is referred to as susceptibility induced 
relaxation. Water molecules diffuse through the magnetic field gradients around the 
particles and the protons are relaxed by an outer sphere mechanism. The protons 
experience spin dephasing and transverse relaxation. As a consequence, T2 is 
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shortened and the signal intensity on T2 weighted images decreases. In addition to 
their effect on T2, these agents also induce faster T1 relaxation. Anyhow, they are 
commonly used as negative CA. The term outer sphere accounts for interactions 
between paramagnetic ions and closely diffusing water molecules, whereas inner 
sphere describes the relaxation of protons of water molecules directly bound to the 
CA. 
 
Paramagnetic contrast agents 
Paramagnetic CA are metal ions with unpaired electrons such as gadolinium (Gd3+), 
manganese (Mn2+, Mn3+), iron (Fe2+, Fe3+), lanthanide (La3+) and dysprosium (Dy3+). 
All of them have already been used in MRI. Paramagnetic CA are shortening the 
relaxation time T1 and induce therefore positive contrast. 
By far, the most prominent type of paramagnetic CA consists of complexes with the 
Gd3+ ion. The ideal suitability of gadolinium results from a high magnetic moment 
given by seven unpaired f-electrons, the symmetric electronic state, high relaxivity 
and a coordination number of nine (Figure 4).  
Gd
64 157.25
[Xe]4f75d16s2
atomic
number
atomic
weight
electron
configuration
 
Figure 4. Electron configuration and atomic data of the rare earth metal gadolinium. 
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However, free heavy metal ions like Gd3+ are toxic and can not be applied in their 
ionic form. Damage to bone, spleen and liver occurs and furthermore free Gd3+ can 
cause nephrogenic systemic fibrosis (NSF) (11). For clinical use it must be bound in 
a complex to guarantee high stability and resistance towards transmetallation. The 
endogenous metal ions Zn2+ and Ca2+ are competitors and thus, the chelator has to 
exhibit higher complexation selectivity for Gd3+ than for Zn2+ and Ca2+. To fulfil these 
requirements two types of polyaminocarboxylic acid derived ligands are employed. 
They are throughout based on the structural backbone of the linear 
diethylenetriaminepentaacetic acid (DTPA) or the macrocyclic 1,4,7,10-
tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA) (7).  
Gd chelates derived from these ligands have a coordination number of nine. Eight 
coordination sites are occupied by N and O of the multidentate ligands and one by a 
H2O molecule, which is crucial for contrast enhancement (Figure 6).  
The overall relaxivity is influenced by several physico-chemical parameters (4): 
• the number of inner sphere water molecules directly bound to Gd3+ 
• the residence time τm of the coordinated water molecule 
• the rotational correlation time τr representing the molecular tumbling time of 
the complex (the slower the Gd3+ complex tumbles, the faster the relaxation 
rate) 
• interaction of the complex with water molecules in the outer sphere 
• electronic parameters 
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Figure 5 provides a schematic view on the interaction of Gd3+ with water molecules. 
 
 
Figure 5. Interaction of Gd3+ with water molecules. 
 
Low molecular weight contrast agents like Gd-DTPA (Magnevist®), Gd-DTPA-BMA 
(Omniscan®), Gd-DTPA-BMEA (OptiMARK®), Gd-BOPTA (MultiHance®), Gd-EOB-
DTPA (Primovist®) and the cyclic Gd-DOTA (Dotarem®), Gd-HP-DO3A (ProHance®) 
and Gd-BT-DO3A (Gadovist®) are clinically approved and currently in use. 
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Figure 6. Clinically used low molecular weight contrast agents. 
 
A rigorous drawback in the use of low molecular weight CA (mw < 1000 Da) is that 
they suffer from the disadvantage of diffusion from the vasculature into the interstitial 
space and rapid renal excretion (12). 
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Nanoparticles as CA for MRI 
Contrast media in which numerous Gd(III) ions are covalently attached to a 
nanosphere are promising to overcome the limitations of low molecular weight 
agents. It is supposed that macromolecular contrast media (mw > 30000 Da) define a 
blood-tissue barrier comparable to the existing barrier for large molecular 
endogenous substances in the blood like plasma proteins and hematopoietic cells 
(13). These so called ´´Blood Pool Agents´´ are designed for prolonged intravascular 
retention and hence increasing molar relaxivities from the vasculature over an 
extended period of time.  
Among a variety of nanosized carriers used for the attachment to gadolinium 
chelates, dextran is investigated due to its well established safety profile and 
biocompatibility. It can be synthesized to integrate a high density of gadolinium 
without intra-molecular cross-linking (14). Furthermore, it has a large number of 
hydroxyl groups suitable for additional conjugation to drugs.  
Nanoparticles consisting of a polysaccharide backbone covalently derivatized with 
gadolinium complexing chelating ligands have also been studied and indicated 
enhanced T1 relaxivity (15).  
Another type of macromolecular carrier are liposomes. They can be formed in 
different diameters varying from 20 - 400 nm with incorporated contrast enhancing 
substances. A rigorous drawback in the development of liposomes as nanosized 
contrast media is their polydispersity which hinders a reproducible synthesis (12). 
The syntheses of polyethylene glycol attached lysine cascades nanosphere have 
also been reported and indicated strong, prolonged MRI enhancement of vessels 
(16). 
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Much attention has been paid to the possible application of dendrimers as 
nanospheres for macromolecular contrast agents (12,17,18,19,20). Dendrimers are 
highly branched synthetic polymers with a well defined structure, which can be 
prepared to specific sizes with reproducibility. 
Gadolinium loaded albumins as macromolecular contrast agents have been 
investigated since 1987 when Gd-DTPA was covalently linked via amide formation to 
albumin molecules (21). The convenience of using serum proteins is based on their 
biocompatibility, stability and extended intravascular retention. Conjugations of Gd-
DTPA or Gd-DOTA derivatives to albumin show high relaxivities and moreover, they 
are comparatively cheap and can easily be obtained (12,22).  
A non covalent attachment of a DTPA derivative to human serum albumin is the 
strategy of MS 325 (23,24). This albumin targeted agent is specifically designed for 
blood vessel imaging. It is clinically approved and commercially available under the 
trademark Vasovist®. In this molecule, the DTPA backbone was modified by a 
phosphodiester linked biphenylcyclohexyl moiety (Figure 7). MS 325 binds reversibly 
human serum albumin in plasma.  
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Figure 7. MS-325. 
 
Bifunctional chelating agents 
Attachment of the multidentate chelating DTPA or DOTA derived ligands to a 
nanosphere requires a functional group for conjugation. This functionality may not be 
involved in coordination to the Gd3+ ion and hence, destabilize the complex. 
To avoid possible weakening of the gadolinium complexation that may lead to the 
release of free Gd3+ ions and cause undesirable side effects, a number of bifunctional 
chelating agents (BFCA) have been developed (18,25,26). Bifunctional chelators can 
bind tightly to the metal ion, while a further functionality acts as a linker to the 
macromolecule. In the case of MS 325 the additional functionality is the 
phosphodiester linked biphenylcyclohexyl moiety at the DTPA backbone (Figure 7). 
Although, it does not provide covalent conjugation, it enables binding to albumin 
without using the carboxylic acid functionalities which are necessary for metal 
coordination.  
Another BFCA is 2-(para-aminobenzyl)-diethylenetriaminepentaacetic acid (NH2-Bn-
DTPA) which has an aminobenzyl residue attached (Figure 8). This residue is 
 37
suitable for the attachment to macromolecules. The coupling strategies to proteins of 
this BFCA will be discussed later in this thesis. 
N
NN
H2N
O
O
O
OO
OH
OH
OH
HO
OH
 
Figure 8. Bifunctional chelating agent NH2-Bn-DTPA. 
Targeting contrast agent 
A remarkable perspective in MRI provides the introduction of a tissue specific 
targeting moiety to the contrast agent. High local concentration of contrast enhancing 
material at a particular site within the human body enables precise medical diagnosis 
and will become an essential tool in tracking the progress of therapies. Currently, 
great effort is invested in the development of such tissue specific contrast agents. 
The concept of liver targeting is realized by the introduction of lipophilic moieties to 
the contrast agent or alternatively, the encapsulation of Gd-DTPA or Gd-DOTA 
chelates into liposomal nanoparticles (27).  
Development of MRI contrast agents with the capability of seeking out tumors is 
approached by different strategies. One proposal is the non-covalent interaction of 
contrast agents bearing charged residues with charged groups of polyornithine and 
polyarginine. It is known, that positively charged polyaminoacids selectively bind to 
tumors as their charge is more negative than that of non-tumor cells (28). Receptor 
targeting through monoclonal antibodies attached to contrast enhancing molecules is 
also widely investigated in this field of research. Monoclonal antibodies are an 
important category of targeting vectors and can be prepared to interact with a variety 
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of receptor sites (29). Recently, the preparation and investigation of a peptide 
targeted contrast agent for molecular magnetic resonance imaging of fibronectin-
fibrin complexes in tumor tissues was published (30). 
The ability of imaging and diagnosing atherosclerotic plaques is of considerable 
interest since atherosclerotic diseases are among the leading causes of death in 
developed countries. Investigated methods to face the challenge of imaging fatty 
deposits include the application of recombinant high density lipoprotein (HDL) like 
nanoparticles (31). Newly published investigations provide characterization of plaque 
in deep seated arteries using motexafin gadolinium (32). MS 325, a gadolinium 
chelate that reversible binds to albumin in plasma has also been applied and areas of 
high signal intensity have been observed and were suggested not only to reflect the 
increased plaque vascularity but also the leakiness of the microvessels (33). In 
principle, also unspecific macromolecular or low molecular weight contrast agents 
suitable for imaging the blood pool bear the potential of indicating pathological 
alteration of the vasculature (34).  
 
Lectins as target specific molecules 
A group of biomolecules, with the capability to recognize specifically carbohydrate 
moieties of complex glycoconjugates and reversibly bind them are lectins. Lectins are 
non enzymatic glycoproteins usually of plant origin which possess carbohydrate 
recognition domains with specificities to various mono and oligosaccharides. The 
selectivity of lectins is determined by the exact shape of the binding site and the 
nature of amino acid residues to which the carbohydrate binds (35).  
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Recognition of carbohydrates on cell-surfaces by lectins has wide application in 
biological processes, including opsonization of microbes (enhancing phagocytes by 
coating a microbe), cell activation and differentiation, cell adhesion and migration, 
and apoptosis (36). Carbohydrate recognition by lectins often involves the side 
chains of tyrosine, tryptophan and histidine residues (37). Substitution of one or more 
amino acid residues leads to significant changes in lectin specificity. The 
carbohydrate is linked to the lectin by hydrogen bonds, van der Waals and 
hydrophobic interactions.  
Purified lectins are routinely applied in the determination of human blood groups (A, 
B, AB or 0). 
A targeting group capable of binding to endothelial cells is the tomato derived lectin 
LEA (Lycopersicon esculentum agglutinin) (38,39). Lectins connected to endothelial 
surfaces remain associated with the vascular wall for 2-3 h. Consequently, when LEA 
is conjugated to a CA, long MRI acquisition times and therefore high spatial 
resolution should be attainable (40). The ability of imaging blood vessels and 
prolonged intravascular retention of LEA conjugated gadolinium loaded latex 
nanoparticles has already been proven (41). 
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Scope of the thesis 
Research in the field of magnetic resonance imaging contrast agents is an area of 
vast dimensions. The development of clinically applicable CA requires collaboration 
in multidisciplinary teams derived from sciences like chemistry, physics and 
medicine. Design, synthesis and evaluation of Gd3+ chelators as well as the choice of 
a suitable nanosphere and adequate linking strategies have to be investigated. The 
necessity of combination with tissue targeting molecules is a further demand which 
has to be fulfilled in order to face today challenges of increasing rates of cancer and 
atherosclerotic diseases. Finally, in vivo behavior and pharmacokinetic aspects have 
to be evaluated. 
In an effort to develop improved nanosized MRI CA, the aim of this thesis focused on 
the evaluation of strategies for the conjugation of a bifunctional chelating ligand to a 
carrier protein. As described above, strong coordination of the contrast enhancing 
metal and additional coupling to carrier molecule is of great importance. For this 
purpose, a newly developed active ester was employed to link between the ε-amines 
of lysine and the BFCA (Figure 8). Due to good characterization possibilities, the 
reaction was developed and optimized by the employment of the test systems Fmoc-
lysine and polylysine. Later, the method was adapted to modify human serum 
albumin (HSA).  
In addition to the active ester strategy, further techniques to attach multiple BFCA to 
HSA, employing glutaric acid anhydride and glutaraldehyde, were investigated and 
subsequently, the relaxation behavior of the prepared CA was evaluated. 
Furthermore, conjugation of the gadolinium modified albumins and the endothelial 
cell targeting LEA for the preparation of tissue specific nanoparticles was performed. 
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Several methods for the nanoparticle preparation in different sizes were evaluated 
and as well tested on their impact on relaxation. 
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Abstract 
Lysine is an important moiety of macromolecules with the capability of convenient 
modification. Attachment of ligands to these amino acids is a crucial step in the 
development of protein or peptide based diagnostic facilities. Here, a new active 
ester mediated methodology is described which enables functionalization of the ε-
amines of Fmoc lysine and poly-L-lysine by the covalent coupling to a bifunctional 
chelating agent. Bromoacetylation of lysine and subsequent n-alkylation of the 
primary amine functionality of the bifunctional chelating agent were performed in 
moderate to good yields. The synthesized compounds were reliably characterized by 
NMR. 
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Introduction 
Due to high spatial resolution and the capacity of differentiating soft tissues magnetic 
resonance imaging (MRI) has become the most widespread imaging modality. Based 
on its most prominent advantage - non invasiveness – MRI today is routinely applied 
for the visualization of internal structures. In clinical diagnosis and biomedical 
research information from three dimensions can easily be obtained without damaging 
tissue or the investigated sample. Furthermore, no exposure to potentially harmful 
ionizing radiation occurs. The potential of MRI can be increased by the application of 
contrast enhancing agents. Currently, Gd(III) chelates are the most frequently used 
MRI contrast agents (1,2). Among all known elements gadolinium exhibits the 
strongest effect on the longitudinal relaxation time. Though, free Gd(III) is toxic and 
the choice of a proper ligand is essential to prevent dissociation of the complex (3). 
Gadolinium chelating ligands of clinically approved contrast agents (CA) are 
throughout based on the structural backbone of the linear 
diethylenetriaminepentaacetic acid (DTPA) or the macrocyclic 1,4,7,10-
tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA). Such 
polyaminocarboxylic acid derived paramagnetic chelates like Gd-DTPA 
(Magnevist®), Gd-DTPA-BMA (Omniscan®), Gd-DTPA-BMEA (OptiMARK®), Gd-
BOPTA (MultiHance®), Gd-EOB-DTPA (Primovist®) and the cyclic Gd-DOTA 
(Dotarem®), Gd-HP-DO3A (ProHance®) and Gd BT-DO3A (Gadovist®) are currently 
in use (4). Nevertheless, these low molecular weight agents suffer from the 
inconvenience of diffusion from the vasculature into the interstitial space and rapid 
renal excretion (5). 
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The concept of attaching Gd(III) chelates to nanospheres presents promising options 
for improved biophysical and pharmacological properties. Increased rotational 
correlation time for enhanced relaxivity per gadolinium atom and the prolonged 
intravascular retention provide the main advantages. Such macromolecular contrast 
media may define a blood-tissue barrier comparable to the existing barrier for large 
molecular endogenous substances in the blood like plasma proteins (6).  
Among many macromolecular carriers for the preparation of contrast enhancing 
nanoparticles dextran is investigated due to its well established safety profile and 
biocompatibility. It can be synthesized to integrate a high density of gadolinium 
without intramolecular cross-linking (7). Liposomes are a different type of nanosized 
carrier and can be formed in different diameters for the incorporation of Gd(III) 
chelates (5). Much attention has also been paid to the potential application of 
dendrimers as nanospheres for macromolecular contrast agents (5, 8, 9, 10, 11). 
Dendrimers are highly branched synthetic polymers with a well defined structure and 
can be produced to specific sizes with reproducibility. A further important class of 
nanoparticular contrast agents are gadolinium loaded albumins. They have been 
investigated since 1987 when Gd-DTPA was covalently linked via amide formation to 
albumin molecules (12). The convenience of using serum proteins is based on their 
biocompatibility, stability and extended intravascular retention. Research also 
covered investigation in paramagnetically labelled polylysine (13,14). Gd(III) chelates 
covalently conjugated to polylysine have been extensively tested in order to find the 
optimal preparation for blood pool imaging (15). Additionally, grafted co-polymeric 
nanoparticles derived from polyethyleneglycol and polylysine cascades loaded with 
Gd-DTPA have been examined and showed prolonged MRI enhancement of blood 
vessels (16). 
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To prevent the relaese of free Gd(III) by a possible weakening of the gadolinium 
complex while attached to a nanosphere a number of bifunctional chelating agents 
(BFCA) have been developed (10, 17, 18). Bifunctional ligands can bind tightly to the 
metal ion while a further functionality acts as a linker to the macromolecule. 
The importance of modifying lysine is shown by the versatile applicability of its 
polymer by the given examples from literature and by the fact that carrier proteins like 
serum albumins contain several lysine moieties capable for the conjugation with 
gadolinium chelating molecules like DTPA or bifunctional derivatives thereof. 
Furthermore, the adaptation of lysine residues plays a crucial role in the adjustment 
of antibodies for the purpose of targeted diagnosis and targeted drug delivery. In this 
study an active ester mediated coupling strategy for the conjugation of Fmoc-lysine 
or polylysine to a bifunctional chelating agent is presented. Development of a test 
system and the following application of the method to the bifunctional chelating agent 
are also reported. The activation of lysine at the terminating ε-amine was followed by 
conjugation to the primary amine functionality of the bifunctional chelating agent. 
 
 
Experimental Section 
Materials and Methods. Bromoacetic acid, N,N-diisopropylethylamine (DIPEA) and 
polylysine hydrobromide (mw: 15000 - 30000) were purchased from Sigma-Aldrich 
(Germany). 2,3,5,6-tetrafluorophenol, dimethylformamide (DMF, extra dry) and 
sodium iodide were obtained from Acros (Belgium). N,N´-dicyclohexylcarbodiimide 
(DCC), 4-aminobenzoic acid and Fmoc-L-lysine hydrochloride were purchased from 
Fluka (Germany). 2,6-Dimethylpyridine (lutidin) was received from Merck (Germany). 
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2-(para-Aminobenzyl)-diethylenetriaminepentaacetic acid tetrahydrochloride (p-NH2-
Bn-DTPA•4 HCl) was prepared according to literature procedures (19). All other 
solvents were obtained from different commercial suppliers and distilled prior use. 
For column chromatography, silica gel 60 from Fluka was used. NMR spectra were 
recorded at 24 °C on a Bruker Avance DPX 400 spectrometer (Ultrashield magnet) at 
400.13 MHz (1H) and 100.63 MHz (13C). Elemental analyses were carried out with a 
Perkin-Elmer 2400 CHN elemental analyzer or by titration with an automatic titration 
system using 0.1 M AgNO3 (DL 21, Mettler-Toledo, 1990) after Schöniger-
decomposition (for Br), respectively at the Microanalytical Laboratory of the 
University of Vienna. 
Bromoacetic acid, 2,3,5,6-tetrafluorophenylester (1). Bromoacetic acid (1.13 g, 8.15 
mmol) and  2,3,5,6-tetrafluorophenol (1.36 g, 8.20 mmol) were dissolved in 30 ml 
CH2Cl2 and cooled to 0°C. A small amount of molecular sieve (3 Å) was added. DCC 
(1.88 g, 9.12 mmol) was dissolved in dichloromethane (15 ml) and added slowly to 
the reaction mixture. The reaction mixture was stirred at 0°C for 45 min. Then, the 
cooling bath was removed and the reaction mixture was allowed to stir further 45 min. 
at ambient temperature. Thereafter, the organic layer was extracted four times with 
water, dried over anhydrous Na2SO4 and evaporated under reduced pressure. 
Finally, the product was purified by Kugelrohr distillation (1.2×10-1 mbar, 63°C) to 
yield the product 1.95 g (6.80 mmol, 83%) as colorless oil.  
1H NMR (CDCl3): δ= 4.14 (s, 2H), 7.04 (m, 1H); 13C NMR (CDCl3): δ= 23.7 (CH2), 
104.1 (t, CH, Ar), 129.3 (C, Ar), 139.6 – 141.7 (m, CF, Ar ), 145.2 – 147.3 (m, CF, 
Ar), 163.6 (CO); Elemental analyses: calcd for C8H3BrF4O2 (Mw= 287.00) : C, 33.48; 
H, 1.05; Br, 27.84. Found: C, 33.50; H, 0.95; Br, 28.39. 
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6-(2-Bromo-acetylamino)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-hexanoic acid 
(2). Fmoc protected lysine hydrochloride (0.10 g, 0.25 mmol) was dissolved in dry 
DMF under an Ar atmosphere. The solution was cooled to 0°C and DIPEA (0.1 ml, 
0.547 mmol) was added slowly via syringe. Thereafter, the reaction mixture was 
stirred for 40 min. Bromoacetic acid, tetrafluorophenyl ester (1) (76 mg, 0.26 mmol) 
was dissolved in DMF (1 ml) and then added dropwise during 15 min. to the reaction 
mixture. Afterwards, the solution was stirred for 2 h at 0°C and one additional hour at 
ambient temperature. Finally, the solvent was evaporated at 60°C under reduced 
pressure. The product was purified by column chromatography (CHCl3:CH3:NH3; 
12:4:1; Rf: 0.3) and yielded 2 (0.73 g, 61%). 
MS (ESI-) m/z 488.8 [M-H]-; 1H NMR (DMSO-d6): δ = 1.31 (m; 2H, CH2-CH2-CH2), 
1.39 (m; 2H, CH2-CH2-CH2), 1.59 - 1.68 (m; 2H, CH-CH2-CH2), 3.06 (m; 2H, NH-CH2-
CH2), 3.86 (m, 1H, NH-CH-COOH), 4.01 (s, 2H, CH2Br), 4.20 - 4.30 (m; 3H,CH-CH2-
O), 7.33 (dd; 2H Ar-H, J= 7.5 Hz), 7.41 (dd; 2H, Ar-H, J= 7.5 Hz), 7.47 (s; 1H, NH), 
7.72 (d; 2H, Ar-H, J= 7.9 Hz), 7.89 (d; 2H, Ar-H, J= 7.9 Hz ), 8.21 (bs; 1H, NH). 13C 
NMR (DMSO-d6): δ = 22.9 (CH2-CH2-CH2), 28.5 (CH2Br), 29.8 (CH2-CH2-NH), 31.5 
(CH2-CH2-CH-COOH), 42.7 (CH2-NH), 46.9 (CH-CH2-O), 54.4 (NH-CH-COOH), 65.5 
(CH-CH2-O), 120.1 (Ar-CH), 125.3 (Ar-CH), 127.1 (Ar-CH), 127.6 (Ar-CH), 140.7 (Ar-
C), 143.8 (Ar-C), 155.9 (NH-COO), 165.8 (COOH), 173.9 (NH-CO-CH2).  
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2-(9H-fluoren-9-ylmethoxycarbonylamino)-6-[2-(4-hydroxycarbonylphenyl) 
acetylamino)]-hexanoic acid (3). para-Aminobenzoic acid (10 mg, 0.06 mmol) and 
NaI (13 mg, 0.09 mmol) were suspended in dry DMF (1 ml) and cooled to 0°C. 
DIPEA (0.04 ml, 0.23 mmol) was added and the reaction mixture was stirred for 10 
min. Bromoacetylated Fmoc-lysine (2) (22 mg, 0.04 mmol) was dissolved in DMF (0.5 
ml) and added slowly to the reaction mixture. Afterwards, the reaction was allowed to 
proceed for 4 h at 0°C. Then, the cooling bath was removed and stirring continued for 
21 h at room temperature. The solvent was removed at 60°C under reduced pressure 
and the product was separated from excess reagents by column chromatograpy 
(CHCl3:CH3:NH3; 12:4:1; Rf: 0.1) to give 3 (21 mg, 88%).  
MS (ESI+) m/z 546.4 [M+H]+; 1H NMR (DMSO-d6): δ = 1.22 (m; 2H, CH2-CH2-CH2), 
1.35 (m; 2H, CH2-CH2-CH2), 1.56 (m; 1H, CH-CH2-CH2), 1.67 (m; 2H, CH-CH2-CH2), 
3.04 ((m; 2H, NH-CH2-CH2), 3.66 (m, 3H, NH-CH-COOH; NH-CH2-CO), 4.21-4.25 
(m, 3H, CH-CH2-O), 6.53 (d, 2H, Ar´-H, J= 8.5 Hz), 7.31 (m, 2H, Ar-H), 7.40 (m, 2H, 
Ar-H), 7.66 (m, 4H, Ar-H;Ar´-H), 7.88 (d, 2H, Ar-H, J= 7.5 Hz), 7.89 (bs; 1H, NH). 13C 
NMR (DMSO-d6): δ = 22.4 (CH2-CH2-CH2), 30.7 (CH2-CH2-NH), 31.2 (CH2-CH2-CH-
COOH), 38.3 (CH2-CH2-NH), 46.3 (CO-CH2-NH), 54.0 (NH-CH-COOH), 111.2 (Ar´-
CH), 117.9 (Ar´-C-COOH), 120.1 (Ar-CH), 121.4 (Ar-CH), 127.3 (Ar-CH), 128,9 (Ar-
CH), 130.8 (Ar´-CH), 131.1 (Ar-CH), 137.4 (Ar-C), 139.4 (Ar-C), 142.6 (Ar´-C), 151.7 
(NH-COO), 152.8 (Ar-COOH), 167,8 (NH-CO-CH2), 169.4 (COOH). 
 
Preparation of 4 by coupling of the BFCA to the bromoacetylated Fmoc-Lysine (2). p-
NH2-Bn-DTPA•4 HCl (21 mg, 0.03 mmol) and NaI (9 mg, 0.06 mmol)  were dissolved 
in dry DMF (1 ml) and cooled to 0°C. DIPEA (0.05 ml, 0.29 mmol) was added and the 
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reaction solution was stirred for 20 min. Then, bromoacetylated Fmoc-lysine (2) (15 
mg, 0.03 mmol) was dissolved in DMF (0.5 ml) and dropped during 30 min. to the 
reaction mixture. Thereafter, the reaction was allowed to stir for 20 h at 0°C. The 
solvent was evaporated under reduced pressure at 50°C to give the product 4. 
MS (ESI-) m/z 905.9 [M-OH]- 
 
Preparation of 5 by the bromoacetylation of polylysine hydrobromide. Under an 
atmosphere of argon polylysine hydrobromide (35 mg) was suspended in a mixture of 
DMF (4 ml) and 2,6-dimethylpyridine (lutidine) (1 ml). The suspension was cooled to 
0°C and active ester 1 (184 mg, 0.64 mmol) dissolved in DMF (1 ml) was added 
during 20 min. The suspension was stirred for 18 h. The resulting clear solution was 
added dropwise to a 1:1 mixture of ethanol and diethylether (40 ml) to precipitate the 
product. The solid was filtered off, washed with ethanol/diethylether (1:1) and dried in 
vacuum to yield the bromoacetylated polylysine (5) (40 mg, 97%). 
1H NMR (DMSO-d6): δ = 1.15-1.80 (m, 6H, CH-CH2-CH2-CH2-CH2), 3.04 (m, 2H, 
CH2-NH), 3.84 (s, 2H, CH2-Br), 4.25 (m, 1H, CH), 7.76 (m, 2H, NH). 
 
Preparation of 6 by coupling of the BFCA to the bromoacetylated polylysine (5). p-
NH2-Bn-DTPA•4 HCl (48 mg, 74.5*10-3 mmol) was dissolved in dry DMSO (2 ml) and 
cooled to 0°C. DIPEA (0.08 ml, 0.46 mmol) was added slowly and the reaction 
solution was stirred for 20 min. Then, bromoacetylated polylysine (5) (11 mg) and NaI 
(9 mg, 0.06 mmol) were dissolved in DMSO (0.5 ml) and added dropwise over 30 
min. to the reaction mixture, which was allowed to stir for 20 h at 0°C. The solution 
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was added dropwise to a 1:1 mixture of ethanol and ether (40 ml) to precipitate the 
product. The solid was filtered off, washed with ethanol/ether (1:1) and dried to yield 
the desired product 6 (19 mg, 65%). 
1H NMR (DMSO-d6): δ = 0.86 (m, 2H, CH-CH2-CH2), 1.06 (m, 2H, CH2-CH2-NH), 
1.24 (m, 2H, CH-CH2-CH2), 1.99 (m, 1H, NH), 2.10-2.85 (m, 8H, N-CH2-CH2-N; N-
CH-CH2-N; Ar-CH2), 2.90-3.89 (m, 14H, CH2-NH-CO; CH2-COOH; NH-CH-CO), 6.49 
(m, 2H, Ar-H), 6,82 (Ar-H). 
 
 
Results and Discussion 
The development of an active ester mediated attachment of a bifunctional chelating 
agent to lysine residues of peptides or carrier proteins for the purpose of MRI 
diagnosis and potential drug delivery started with the choice of a suitable test system. 
Economical reasons due to expensive reagents and easy handling and 
characterization of the employed replacement substances facilitated development 
activities. 
Fmoc protected lysine was favored due to good characterization conditions. 
Modifications at any position can easily be identified by nuclear magnetic resonance 
(NMR) and electrospray ionization mass spectrometry (ESI-MS). Separation from 
excess reagent without significant loss of product is straight forward using column 
chromatography. 
In comparison to the bifunctional chelating agent p-NH2-Bn-DTPA - containing five 
carboxylic acid functionalities and several methylene positions - the replacement 
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compound para-aminobenzoic acid consists of aniline and just one carboxylic acid 
functionality. The simple structure is easily characterized by NMR. This fact qualified 
para-aminobenzoic acid as a well applicable substitution for the BFCA. 
Since active esters of bromoacetic acid like 4-nitrophenyl or N-succinimidyl esters 
provide low selectivity for acylation in the presence of primary amine groups a 
significant amount of n-alkylated side products will be formed. In contrast, the 
employment of stable bromoacetic acid esters of electron deficient phenols as 
activation reagent showed the predominant formation of the desired bromoacetylation 
product and marginal n-alkylation side reactions (20). Beyond that, fluorophenyl 
esters display better stability towards hydrolysis in basic aqueous solutions than the 
corresponding N-hydroxysuccinimide ester. The esterification proceeded by the 
employment of DCC to activate the carboxylic functionality. The product (1) was 
obtained in 83% yield after purification by Kugelrohr distillation. 
Bromoacetylation of Fmoc lysine succeeded under amide formation at the terminal ε-
amine of the amino acid with active ester (1). After isolation of the product (2) the 
NMR spectrum indicated that no undesired n-alkylation - side reaction occurred. 
Purified 2 was obtained in 61% yield (Figure 1). 
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Figure 1. Bromoacetylation of Fmoc lysine. 
 
The following n-alkylation of the primary amine of p-aminobenzoic acid and the 
bromoacetate (2) was performed under alkaline conditions to give 3 in 88% yield, 
after purification by column chromatography (Figure 2). 
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Figure 2. N-alkylation of para-aminobenzoicacid with 2. 
 
Following this successful n-alkylation, the same conditions were applied to the 
conversion of the bromoacetylated Fmoc lysine and p-NH2-Bn-DTPA into the 
bifunctional ligand. Unfortunately, the resulting product was difficult to isolate from 
unconverted material by column chromatography. Nevertheless, ESI-MS data 
indicated the presence of 4 (Figure 3). 
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Figure 3. N-alkylation of p-NH2-Bn-DTPA with 2. 
 
Polylysine of different molecular weight fractions are well characterized and 
commercially available. This polyamino acid is non-immunogenic and biodegradable. 
Acylated polylysine derivatives have already been explored as drug carrier (21,22). 
The bromoacetylation of polylysine was carried out by the adaptation of a literature 
procedure (23). A cooled suspension of polylysine hydrobromide in a mixture of DMF 
and 2,6-lutidine was treated with the active ester 1. Overnight, the suspension formed 
a clear solution. This indicated the conversion of the reagents. The bromoacetylated 
product 5 was isolated by precipitation from a 1:1 mixture of ethanol and diethylether. 
The yield was calculated by the ratio of the molecular weight of polylysine 
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hydrobromide (mw: 15000-3000) and the molecular weight of the derivatized product 
5 (mw: 17676-35601). The molecular weight ratio is 1.17. Multiplication of the amount 
of the starting material with 1.17 results in the substance weight for 100% conversion. 
Applying this calculation the reaction gave 97% yield. The product 5 is insoluble in 
water but readily soluble in DMSO.  
Again, n-alkylation with p-NH2-Bn-DTPA was performed under basic conditions and 
the resulting compound was isolated by precipitation from an EtOH/Et2O (1:1) 
mixture. After drying 65% of the product 6 were obtained (Figure 4). 
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Figure 4. Bromoacetylation of polyylsine and subsequent n-alkylation. 
 
In conclusion a novel strategy for the functionalization and covalent conjugation of a 
bifunctional chelating agent to the terminal ε-amines of lysine moieties was 
 62
presented. The bromoacetylation of Fmoc protected lysine and polylysine were 
performed with a novel active ester in good yields. Subsequent n-alkylation with the 
primary amine functionality of the DTPA derivative resulted in the desired products. 
This novel active ester mediated conjugation can be applied to similar systems 
containing biomacromolecules with lysine residues and primary amine groups of low 
molecular weight ligands. 
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Abstract 
With the purpose to develop macromolecular magnetic resonance imaging contrast 
agents, we herein report three different synthetic approaches to the covalent 
attachment of bifunctional chelating agents to human serum albumin followed by 
coordination to contrast enhancing Gd(III). Applied methods cover active ester-
mediated conjugation, linkage through glutaryl spacer, as well as the connection by 
the employment of glutaraldehyde. The content of Gd(III) was evaluated by ICP-MS 
measurements and indicated reproducible amounts of conjugated contrast 
enhancing material. Small angle X-ray scattering experiments provided the size 
dimension and altered shape of the gadolinium loaded proteins in comparison to 
unmodified albumin. Finally, the relaxation behavior of the protein conjugates was 
evaluated and indicated suitability for the use as macromolecular contrast agent. 
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Introduction 
The use of metals as diagnostic agents has become a powerful tool in medicine. 
Especially magnetic resonance imaging (MRI) provides a noninvasive and high 
spatial resolution imaging technique (1,2). At present, the most widespread applied 
paramagnetic contrast enhancing metal is the lanthanide gadolinium. Free Gd(III) 
however, is toxic and may harm spleen, liver, bones and can also cause 
nephrogenic systemic fibrosis (NSF) (3). Therefore, stable polyaminocarboxylic acid 
derived gadolinium chelates are commonly employed.  
Gadolinium chelating ligands of clinically approved contrast agents (CA) are 
throughout based on the structural backbone of the linear 
diethylenetriaminepentaacetic acid (DTPA) or the macrocyclic 1,4,7,10-
tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA). Paramagnetic 
gadolinium compounds with multidentate ligands like Gd-DTPA (Magnevist®), Gd-
DTPA-BMA (Omniscan®), Gd-DTPA-BMEA (OptiMARK®), Gd-BOPTA 
(MultiHance®), Gd-EOB-DTPA (Primovist®) and the cyclic Gd-DOTA (Dotarem®), Gd-
HP-DO3A (ProHance®) and Gd BT-DO3A (Gadovist®) are currently in use (4). 
Though, these low molecular weight agents suffer from the disadvantage of diffusion 
from the vasculature into the interstitial space and rapid renal excretion (5). 
Contrast media in which numerous Gd(III) ions are covalently attached to a 
nanosphere have shown promise to overcome the limitations of low molecular weight 
agents. It is supposed that macromolecular contrast media define a blood-tissue 
barrier comparable to the existing barrier for large molecular endogenous 
substances in the blood like plasma proteins and hematopoietic cells (6). These so 
called Blood Pool Agents have been designed for prolonged intravascular retention 
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and hence, to increase molar relaxivities from the vasculature over an extended 
period of time.  
Among a variety of nanosized carriers used for the attachment to gadolinium 
chelates, dextran is investigated due to its well established safety profile and 
biocompatibility. It can be synthesized to integrate a high density of gadolinium 
without intra-molecular cross-linking (7). Furthermore, it has a large number of 
hydroxyl groups suitable for additional conjugation to drugs. Nanoparticles consisting 
of a polysaccharide backbone covalently derivatized with gadolinium complexing 
chelating ligands have also been studied and indicated enhanced T1 relaxivity (8). 
Another type of macromolecular carrier are liposomes. They can be formed in 
different diameters varying from 20 to 400 nm with incorporated contrast enhancing 
substances. A rigorous drawback in the development of liposomes as nanosized 
contrast media is their polydispersity which hinders a reproducible synthesis (5). The 
syntheses of polyethylene glycol attached lysine cascades nanospheres have also 
been reported and indicated strong, prolonged MRI enhancement of vessels (9). 
Much attention has been paid to the possible application of dendrimers as 
nanospheres for macromolecular contrast agents (5,10,11,12,13). Dendrimers are 
highly branched synthetic polymers with a well defined structure and can be 
produced reproducibly with specific sizes. Gadolinium loaded albumin as 
macromolecular contrast agents has been investigated since 1987 when Gd-DTPA 
was covalently linked via amide formation to albumin molecules (14). The 
convenience of using serum proteins is based on their biocompatibility, stability and 
extended intravascular retention. Conjugations of Gd-DTPA or Gd-DOTA derivatives 
to albumin show high relaxivities and moreover, they are comparatively cheap and 
can easily be obtained (5,15). A non covalent attachment of a DTPA derivative to 
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human serum albumin is the strategy of the chelator MS 325 (16,17). This albumin 
targeted agent is specifically designed for blood vessel imaging. It is clinically 
approved and commercially available under the trademark Vasovist®. In this 
molecule, the DTPA backbone was modified by a phosphodiester linked 
biphenylcyclohexyl moiety. MS 325 binds reversibly to human serum albumin in 
plasma.  
To avoid possible weakening of the gadolinium complexation that may lead to the 
release of free Gd(III) ions a number of bifunctional chelating agents (BFCA) have 
been developed (12,18,19). Bifunctional ligands have been designed to bind tightly 
to the metal ion while a further functionality acts as a linker to the macromolecule.  
In this study, we introduce three strategies for the covalent conjugation of a 
bifunctional chelating agent to human serum albumin and the complexation to 
Gd(III). The first method describes the activation of human serum albumin (HSA) 
through bromoacetic acid, 2,3,5,6-tetrafluorophenyl ester and subsequent N-
alkylation with the primary amine functionality of 2-(para-aminobenzyl)-
diethylenetriaminepentaacetic acid (NH2-Bn-DTPA). The further techniques enable 
covalent attachment by the application of glutaric acid anhydride and glutaraldehyde. 
The following complexation of the albumin bound DTPA derivative with Gd(III) and 
the evaluation of the amount of chelated metal are reported as well. Additionally, we 
report the structure and size dimension of the Gd(III) labeled albumins shown by 
small angle X-ray scattering (SAXS) measurements. Finally, the effects on the 
relaxation behavior were investigated and will be presented in this paper. 
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Experimental Procedures 
Materials and Methods. Human serum albumin (HSA), phosphate buffered saline 
(1×PBS), bromoacetic acid, glutaric dialdehyde (50 wt.% solution in water), glutaric 
anhydride and sodium cyanoborohydride (NaBH3CN) as well as trisodium citrate 
dihydrate and citric acid monohydrate for buffer preparation were purchased from 
Sigma-Aldrich (Germany). 2,3,5,6-tetrafluorophenol and dimethylformamide (DMF, 
extra dry) were obtained from Acros (Belgium). N-(3-dimethylaminopropyl)-N´-ethyl-
carbodiimide hydrochloride (EDC), N,N´-dicyclohexylcarbodiimide (DCC) and sodium 
bicarbonate were purchased from Fluka (Germany). Trisodium 
bis(nitrilotriacetate)gadolinate solution (Na3[Gd(NTA)2]) (20) as well as 2-(para-
aminobenzyl)-diethylenetriaminepentaacetic acid tetrahydrochloride (NH2-Bn-
DTPA·4 HCl) (21) were prepared according to literature procedures. All water used 
was purified by a Millipore Synergy 185 UV Ultrapure Water System (Molsheim, 
France). NMR spectra were recorded at 24 °C on a Bruker Avance DPX400 
spectrometer (Ultrashield magnet) at 400.13 MHz (1H) and 100.63 MHz (13C). 
Elemental analyses were carried out with a Perkin-Elmer 2400 CHN elemental 
analyzer or by titration with an automatic titration system using 0.1 M AgNO3 (DL 21, 
Mettler-Toledo, 1990) after Schöniger-decomposition (for Br), respectively at the 
Microanalytical Laboratory of the University of Vienna. 
 
Preparation of 3 by active ester mediated conjugation of NH2-Bn-DTPA to HSA. 
Bromoacetic acid, 2,3,5,6-tetrafluorophenylester (1). Bromoacetic acid (1.13 g, 8.15 
mmol) and 2,3,5,6-tetrafluorophenol (1.36 g, 8.20 mmol) were dissolved in CH2Cl2 
(30 ml) and cooled to 0°C. A small amount of molecular sieve (3 Å) was added. DCC 
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(1.88 g, 9.13 mmol) was dissolved in dichloromethane (15 ml) and added slowly to 
the reaction solution. After 45 min. the cooling bath was removed and the reaction 
was allowed to stir for further 45 min. at ambient temperature. Thereafter, the 
organic layer was extracted four times with water, dried over anhydrous Na2SO4 and 
evaporated under reduced pressure. Finally, the product was purified by Kugelrohr 
distillation (1.2×10-1 mbar, 63°C) to yield the product as colorless oil (1.95 g, 6.80 
mmol, 83%). 1H NMR (CDCl3):δ= 4.14 (s, 2H), 7.04 (m, 1H); 13C NMR (CDCl3): δ= 
23.7 (CH2), 104.1 (CH, Ar), 129.3 (C, Ar), 139.6 – 141.7 (CF, Ar ), 145.2 – 147.3 
(CF, Ar), 163.6 (CO); Elemental analyses: calcd for C8H3BrF4O2: C, 33.48; H, 1.05; 
Br, 27.84. Found: C, 33.50; H, 0.95; Br, 28.39. 
Activation of HSA: HSA (53.6 mg, 0.8×10-3 mmol) was dissolved in PBS (12 ml). 
Bromoacetic acid, 2,3,5,6-tetrafluorophenylester (1) (43 mg, 149.8×10-3 mmol) 
dissolved in DMF (1.7 ml) was added slowly to the albumin solution and the pH was 
maintained within a range of 7.8 – 8 by the addition of 0.1 M NaOH. Next, the 
reaction mixture was stirred for 2 h at room temperature. To remove excess reagents 
and small molecular compounds the solution was concentrated by centrifugation 
(Vivaspin 20, MWCO: 30000, 2500×g, 19°C) and repeatedly washed with water 
(three times). 
N-alkylation of NH2-Bn-DTPA (2): The activated HSA was dissolved in 0.1 M 
NaHCO3 (pH 8.1) (10 ml) and NH2-Bn-DTPA·4HCl (46.8 mg, 72.6×10-3 mmol) in 0.1 
M NaHCO3 (2 ml) was added slowly to this solution while maintaining the pH 
between 8 and 8.5 by the addition of 0.3 M NaOH. Afterwards, the reaction mixture 
was stirred for 18 h at room temperature. Finally, the solution was concentrated 
again by centrifugation (Vivaspin 20, MWCO: 30000, 2500×g, 19°C) and repeatedly 
washed with water (three times). 
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Complexation to Gd(III): Albumin conjugated NH2-Bn-DTPA was dissolved in 7 ml 
0.1 M citric buffer (pH 6.5) and cooled to 4°C. 0.1 M Gd(NTA)2 solution (2.5 ml, 0.25 
mmol) was added and allowed to react for 21 h. The solution was concentrated by 
centrifugation (Vivaspin 20, MWCO: 30000, 2500×g, 19°C) and washed with water 
(three times) yielding an aqueous solution of 3. 
 
Preparation of 4 by glutaric anhydride mediated conjugation of NH2-Bn-DTPA to 
HSA. 
Glutarylation of HSA: HSA (53 mg, 0.8×10-3 mmol) was dissolved in 0.1 M NaHCO3 
(10 ml) and cooled to 4°C. Glutaric anhydride (62 mg, 543.4×10-3 mmol) was added 
slowly in small portions. Repeatedly, the pH of the mixture was adjusted within a 
range of 7.8 - 8.2 by addition of 0.6 M NaOH. Then the solution was stirred for 22 h 
at 4°C. Afterwards, the solution was concentrated by centrifugation (Vivaspin 20, 
MWCO: 30000, 2500×g, 19°C) and repeatedly washed with water (three times).  
Linkage to NH2-Bn-DTPA (2): The glutarylated albumin was diluted with H2O (7 ml) 
and NH2-Bn-DTPA·4HCl (60 mg, 931×10-3 mmol) in H2O (2 ml) was added at room 
temperature. During the addition, the pH was kept at 6.8 - 7.2 by addition of 0.3 M 
NaOH. EDC (8 mg) was added to the solution and the conjugation reaction 
proceeded for 2 h at room temperature. For the removal of excess reagents and low 
molecular weight compounds, the solution was concentrated by centrifugation 
(Vivaspin 20, MWCO: 30000, 2500×g, 19°C) and repeatedly washed with water 
(three times). 
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Complexation to Gd(III): Albumin conjugated NH2-Bn-DTPA was then dissolved in 
0.1 M citric buffer (10 ml) (pH 6.5) and cooled to 4°C. 0.1 M Gd(NTA)2 solution (2.5 
ml, 0.25 mmol) was added and allowed to react for 19 h. Finally, the reaction mixture 
was concentrated by centrifugation (Vivaspin 20, MWCO: 30000, 2500×g, 19°C) and 
repeatedly washed with water (three times) to give a purified aqueous solution of 4. 
 
Preparation of 5 by glutaric dialdehyde mediated conjugation of NH2-Bn-DTPA to 
HSA. 
Conjugation and complexation with Gd(III): HSA (49 mg, 0.7×10-3 mmol) and NH2-
Bn-DTPA·4HCl (38.7 mg, 60.1×10-3 mmol) were dissolved in PBS (15 ml) and 
cooled to 4°C. The pH was adjusted with 3 M NaOH to 8.0. Glutaric dialdehyde (1 
ml, 5.52 mmol) was dropped slowly to the reaction mixture and the pH was 
maintained at 7.6 - 8.1 by the addition of 0.1 M NaOH. Then, the mixture was stirred 
for 2 h at 4°C. 2 M NaBH3CN (solution in 0.01 M NaOH) (0.89 ml, 1.782 mmol) was 
added slowly and the pH was adjusted repeatedly to 8.0 with 1 M HCl. Again, the 
solution was stirred for 1 h at 4°C. Finally, the pH was altered to 6.7 by 1 M HCl and 
0.1 M Gd(NTA)2 solution (2 ml, 0.2 mmol) was added at 4°C and allowed to react for 
19 h. The reaction mixture was concentrated and washed with water (three times) by 
centrifugation (Vivaspin 20, MWCO: 30000, 2500×g, 19°C) to yield an aqueous 
solution of 5. 
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Characterization. 
Protein Assay. The protein concentration of purified gadolinium loaded albumin 
solutions was determined by the method of Bradford. A Bradford test kit from Bio-
Rad Laboratories (Vienna, Austria) was used and adapted for usage in 96 - well 
plates. Optical densities at 595 nm were recorded on a microplate reader (Synergy 
HT, Biotek) 15 min. after the addition of the Bradford solution. 
 
Inductively Coupled Plasma Mass Spectrometry (ICP-MS). The gadolinium 
content of the purified albumin solutions was determined by ICP-MS (Agilent 7500ce, 
Waldbronn, Germany), equipped with a CETAC ASX-520 autosampler (Neuss, 
Germany), a Scott double pass spray chamber, and a MicroMist nebulizer. For the 
analysis, the samples were diluted 1:60 000 with 3.5% HNO3 (HNO3 p.a. from Sigma 
Aldrich, further purified with a quartz sub-boiling system from Milestone-MLS GmbH, 
Leutkirch, Germany). Every sample contained 0.5 ppb In as internal standard (CPI 
International, Santa Rosa, CA, USA). The Gd standards were made in the range 
from 23 to 0.1 ppb with a Gd containing solution purchased from Aldrich chemical 
company (Milwaukee, USA). The determined LOQ was 0.059 ppb. 
Small-Angle X-ray Scattering (SAXS). SAXS experiments were performed using a 
rotating anode generator, equipped with a pinhole camera and CuKα radiation 
monochromatized and collimated from crossed Göbel mirrors (Nanostar from Bruker 
AXS, Karlsruhe). The scattered intensities were collected with an area detector 
(Vantec 2000, gas detector with microgap technology). All X-ray patterns were 
radially averaged and corrected for background scattering from the solvent to obtain 
the scattering intensity I(q), where q = (4π/λ)·sinθ is the scattering vector, 2θ the 
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angle between the incident and the diffracted beam and λ = 0.1542 nm the X-ray 
wavelength. The measurements were performed at a sample to detector distance of 
1.1 m from which a q-range from 0.1 - 2.8 nm-1 was covered.  
 
Spin-Lattice and Spin-Spin Relaxivity measurements. Relaxivity measurements 
were performed on a 3 Tesla whole-body MRI scanner (TimTrio 3 T, Siemens 
Medical Solutions, Erlangen, Germany) using a whole body coil for excitation and 
standard head receiver coil for signal reception. Homogeneity of B1-field was insured 
by test measurements before the actual measurements of relaxivity. For each agent 
four dilutions ranging from 0.018 mM to 0.151 mM in PBS with the volume of 1.5 ml 
were prepared. All probes were measured in standard PE-tubes with a diameter of 
0.8 cm. The tubes were placed in the centre of a plastic box surrounded by water 
heated to 37°C. 
For the determination of spin-lattice relaxation times T1, spin echo inversion recovery 
(IR) sequences with inversion times from 0 to 3500 ms (TI = 0, 60, 80, 100, 150, 200, 
250, 300, 400, 500, 750, 1000, 1250, 1500, 1750, 2000, 2500, 3500 ms) were used. 
An adiabatic pulse was applied for B1 insensitive inversion. The other parameters 
were: TR/TE = 5000/8.1 ms; flip angle 180°; 8 turbo factor 11; FOV read 180 × 180 
mm; resolution matrix 192 × 192; bandwidth 260 Hz/pixel; and slice thickness 3 mm. 
The mean values of the signal intensities, the standard deviations, and pixel counts 
were determined by drawing regions of interest. The area assessed measured 
between 0.12 cm2 and 0.14 cm2; for each measurement series, the measured area 
was kept identical by copying and pasting the ROI. For all measurements, the 
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relaxation rates (R1) and the relaxivities (r1) were calculated for each substance. The 
longitudinal relaxation rate (R1) was calculated using the equation: 
 
SI (TI)= A[1-2 exp(-R1*TI)+exp(-R1*TR)] [1] 
 
with SI being the signal intensity as a function of TI, “A” accounting for the thermal 
equilibrium magnetization M0, and TI being the inversion time in ms.  
For the determination of individual spin-spin relaxation times (T2), spin-echo 
sequence with multiple echoes (NE= 5) ranging from 13.8 ms to 69 ms was used. 
Repetition time was set to 2500 ms, FOV 160 × 160 mm, resolution matrix 128 × 
128, bandwidth 260 Hz/pixel; and slice thickness 3 mm. The mean values of the 
signal intensities, the standard deviations, and pixel counts were determined by 
drawing regions of interest. The area assessed measured between 0.12 cm2 and 
0.14 cm2; for each measurement series, the measured area was kept identical by 
copying and pasting the ROI. For all measurements, the relaxation rates (R2) and the 
relaxivities (r2) were calculated for each substance. The transversal relaxation rates 
(R2) were calculated as the reciprocal value of the slope of semilogarithmic plot of 
signal intesities at individual echo times and respective echo times. 
The relaxivities (r1, r2) were calculated as the slope of linear regression of R1 and R2 
as a function of contrast agent concentration. 
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Results and Discussion 
Since active esters of bromoacetic acid like 4-nitrophenyl or N-succinimidyl esters 
provide low selectivity for acylation in the presence of primary amine groups, this 
behavior causes the formation of a significant amount of N-alkylation side products. 
In contrast, the employment of stable bromoacetic acid esters of electron deficient 
phenols as activation reagent results predominantly in the formation of the desired 
bromoacetylation product and little N-alkylation side reactions (22). In addition, 
fluorophenyl esters display better stability towards hydrolysis in basic aqueous 
solutions than the corresponding N-hydroxysuccinimide esters. Furthermore, a 
property of bromoacetyl functionalities is their capability of thioether formation with 
cysteine thiols (23) which may cause a higher degree of protein conjugation. 
The activation of the carrier protein by reaction with 1 proceeded at the ε - amine of 
lysine residues under mild basic conditions. Excessive low molecular weight 
reagents were removed by centrifugation and followed by subsequent N-alkylation 
with the BFCA (2) at pH 7.8 – 8.2. Concurrently, the bromoacetyl group of the active 
ester (1) could have been converted with cystein thiols and thereafter, the acylation 
reaction with the primary amine of the DTPA derivative proceeded. Nonconjugated 
chelating agent was then removed by centrifugation (Figure 1). 
To avoid Gd(III) binding to albumin, the contrast enhancing metal was introduced in 
form of a Gd(NTA)2 solution. Nitrilotriacetic acid is a weak complexant for Gd(III) and 
prevents nonspecific binding of the chelated metal to proteins (24). The 
gadolinium:albumin ratio was determined by the measurement of protein 
concentration by the Bradford assay and the detection of the metal content by ICP-
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MS. This active ester mediated conjugation showed that on average 13 to 15 Gd(III) 
were chelated and covalently attached to each HSA molecule. 
An alternative conjugation strategy is based on the application of glutaric anhydride 
as linker between HSA and the Gd(III) chelator. The covalent attachment of BFCA 
(2) to the albumin was performed using a modified method as described in literature 
(25). The glutarylation of the albumin succeeded by the addition of glutaric anhydride 
in small portions to a cooled solution and repeated correction of the pH to 8. After 
removal of excess anhydride the free carboxylic functionalities of the glutarylated 
protein were activated with the water - soluble carbodiimide EDC. This procedure 
enabled amide formation with the phenylamine residue of the bifunctional DTPA 
derivative 2. Subsequently, the reaction mixture was purified and the Gd(III) 
complexation proceeded overnight. Again the solution was washed and concentrated 
by centrifugation to yield a solution of 4 (Figure 2). Determination of the 
gadolinium:albumin ratio indicated that 35 to 37 Gd(III) ions were attached per 
protein by this technique. It has to be mentioned that in one conjugation experiment 
only 12 Gd(III) atoms per protein molecule were detected. 
In a third attempt to covalently modify HSA with Gd, a glutaraldehyde-mediated 
approach was chosen. Due to its convenient handling this dialdehyde is the most 
popular homobifunctional reagent for crosslinking proteins and the conjugation of 
proteins to other amine containing molecules. In aqueous solutions glutaraldehyde 
forms α,β - unsaturated polymers which are highly reactive towards primary amines. 
The polymer size and structure is unknown and may be influenced by the age of the 
glutaraldehyde solution (23). The linkage of HSA and NH2-Bn-DTPA (2) proceeded 
through the formation of Schiff bases with the ε – amine functionalities of the lysine 
residues of albumin and the primary amine of the chelating agent under mild alkaline 
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conditions. However, the generated Schiff bases are not stable in an acidic 
environment and have therefore been reduced to stable secondary amines. This was 
carried out by the use of a 2 M sodium cyanoborohydride solution. Finally, the 
reaction mixture was acidified and addition of Gd(NTA)2 solution yielded 5 (Figure 3). 
After purification and concentration the protein assay and ICP-MS measurements 
showed an attachment of 3 to 7 gadolinium chelates at each albumin molecule. 
Figure 4 shows the background corrected SAXS data for pure HSA, 3 [with 13 Gd(III) 
per HSA] 4 [35 Gd(III) per HSA] and 5 [7 Gd(III) per HSA]. All data were normalized 
to the scattered volume which is different due to variations in the diameter of the 
capillaries. The scattering intensities were numerically fitted using the programs 
GNOM (26) and DAMMIN (27). These programs vary the three-dimensional 
distribution of small units, visualized by spheres, which represent the electron 
density of the structure. In a Monte-Carlo simulation the density and arrangement of 
these units is adjusted in order to recover three-dimensional structures from the 
experimentally obtained one-dimensional scattering curves. At least five Monte-Carlo 
runs were performed for each sample and a mean electron density map was 
constructed using the program DAMAVER (28). 
Regarding modified albumins a slight increase of the protein sizes is observed 
related to increasing Gd(III) loading. This is visualized in Figure 5 by the radius of 
gyration. The numerical fits of the SAXS data result in a heart shaped structure for 
non modified human serum albumin (Fig. 6a). This corresponds well to literature 
results (29). The scattering contrast arises from the different electron densities of 
HSA and pure water, which can be interpreted as a two phase system. In the case of 
the modified albumins 3 and 5, a three phase system is obtained, which is more 
difficult to interpret. Nevertheless, as shown in Fig. 6b and 6d with an overlay of HSA 
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(bright parts) and the modified albumin (dark parts), the shape of the protein seems 
to change slightly: The higher the Gd(III) content, the more the heart-shaped 
structure seems to open and the shape tends more to be elongated and stretched. 
This is possibly an effect of the additional electrical charge introduced by the ligands. 
In the case of the modified albumin 4, this can be interpreted again as a two-phase 
system, with the scattering contrast arising from the large electron difference 
between the high amount of Gd atoms and the background (pure water and HSA), 
Fig. 6c. As the orientation of the simulations in Figure 6 (HSA and modified albumin, 
respectively) is not fixed, there are a number of possible alignments of the protein 
and the Gd(III) loaded protein with respect to each other. However, as a continuation 
of the structural changes from Figure 6, it is very probable that the gadolinium 
complexes are attached predominantly to the external parts of the biomolecule.  
The Gd(III) loaded albumins were evaluated at 37°C on their ability to modify the 
relaxation rate of water. Relaxation rates (R1, R2) and respective relaxivities (r1, r2) 
measured in PBS at 3T for agents 3 - 5 are given in Table 1. As displayed in the 
table compound 4 has the highest relaxivity of the tested compounds per carrier 
molecule. This corresponds to an r1 of 9.54 mM-1*sec-1 relative to gadolinium 
concentration. Agent 5 showed lower relaxation than 4 which is due to a low number 
of gadolinium ions attached per protein. Though, calculation of r1 of the carrier 
protein to the relaxivity per Gd(III) results in a similar value (7.91 mM-1*sec-1). These 
results indicate that different linkage by glutaric anhydride or glutaraldehyde does not 
alter the molar relaxivity compared to each other, but influence the amount of 
attached Gd(III) significantly. In contrast to 4 and 5 the Gd(III) modified albumin 3 
derived by active ester mediation showed just low relaxivity values and does not 
meet the requirements for the application as a macromolecular MRI contrast agent. 
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In conclusion we presented the feasibility of three different strategies for the covalent 
coupling of a bifunctional Gd(III) chelator to albumin. Characterization of size, shape 
and relaxation behaviour indicated compound 4 as the most promising candidate for 
further investigations. Ongoing studies on the stability of the Gd(III) complexes and 
the degradability of the protein conjugates in living organisms will further elucidate 
the potential application of these compounds as nanosized contrast agents. 
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Tables and Figures 
 
Table 1. Relaxation behavior of the loaded albumins 3 - 5 in dependence of the 
carrier concentration (HSA). 
compound  ccarrier [mM] R1 [s-1] r1 [s-1*mM-1] R2 [s-1] r2[s-1*mM-1] 
3 
13 Gd(III)/HSA 
0.151 1.057 5.807 3.551 15.046 
0.113 0.655 2.608 
0.056 0.386 1.796 
0.026 0.312 1.671 
4 
12 Gd(III)/HSA 
0.151 17.927 114.48 66.590 451.83 
0.113 13.155 39.772 
0.056 6.808 18.516 
0.026 3.555 8.480 
5 
3 Gd(III)/HSA 
0.151 3.897 23.714 17.780 111.41 
0.075 2.237 8.937 
0.037 1.230 4.961 
0.018 0.732 3.003 
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Figure 1. Synthetic scheme of active ester mediated conjugation of Gd(III) chelator 2 at: (a) the ε – 
amines of lysine residues and (b) cysteine thiols. 
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Figure 2. Glutaric anhydride mediated attachment of the BFCA (2) to HSA. 
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Figure 3. Glutaraldehyde mediated conjugation of 2 to HSA and its Gd(III) complex. 
 
 87
 
Figure 4. SAXS intensities in dependence on the scattering vector after subtraction of the 
background. 
 
 
 
Figure 5. Radius of gyration in dependence of the number of Gd(III): pure HSA (white), 3 (red), 4 
(green), 5 (blue). 
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Figure 6. SAXS generated images of pure HSA (a), 13 Gd(III) attached by active ester mediated 
conjugation (b), 35 Gd(III) attached by glutaric anhydride mediated conjugation (c) and 7 Gd(III) 
attached by glutaraldehyde mediated conjugation (d). 
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Abstract 
Human serum albumin (HSA) derived nanoparticles represent promising systems for 
the development of diagnostic agents. Endothelial cell targeting lectins covalently 
conjugated to Gd-HSA combine magnetic resonance imaging (MRI) contrast 
enhancement with the advantages of tissue targeting. The present study reports the 
preparation of Gd(III) loaded albumin-lectin nanoparticles by different strategies for 
their potential exploration as targeted MRI contrast agents. As in vivo behaviour of 
nanoparticles strongly depends on particles dimension, the size as well as the 
polydispersity index has been evaluated for each preparation method. PCS 
measurements indicated a nanoparticles size range between 112 nm and 304 nm. 
Furthermore, the impact on the relaxation behaviour was determined by MRI 
experiments. 
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Introduction 
Gadolinium based contrast agents have become a powerful imaging modality in 
magnetic resonance imaging (MRI). High spatial resolution images of soft tissues are 
provided by this non-invasive diagnostic technique (Caravan et al., 1999; Merbach 
and Toth, 2001). Nevertheless, free Gd(III) is known to be toxic and may cause 
damage to spleen, liver and bones and lead to nephrogenic systemic fibrosis (Sieber 
et al., 2008). Consequently, stable chelates are required. The use of 
polyaminocarboxylic acid ligands like the linear diethylenetriaminepentaacetic acid 
(DTPA), the macrocyclic 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid 
(DOTA) or backbone modified derivatives thereof prevent the release of free Gd(III) 
and hence reduce the risk of the mentioned side effects (Hermann et al., 2008). 
However, the use of low molecular weight contrast agents is limited due to their rapid 
clearance and diffusion from the vasculature into the interstitial space (Barrett et al., 
2006). The attachment of low molecular weight contrast agents to nanospheres 
presents auspicious possibilities for improved biophysical and pharmacological 
properties. Increased rotational correlation time for enhanced relaxvity per gadolinium 
atom and the prolonged intravascular retention - leading to the increase of molar 
relaxivities from the vasculature over an extended period of time - provide the main 
advantages. Such macromolecular contrast media may define a blood-tissue barrier 
comparable to the existing barrier for large molecular endogenous substances in the 
blood like plasma proteins (Brasch and Daldrup-Link, 2003). 
The most common approaches for the preparation of contrast enhancing 
nanoparticles include the conjugation of Gd(III) chelates to dextrans (Sirlin et al., 
2004), dendrimers (Langereis et al., 2006; Xu et al., 2007a; Xu et al., 2007b; Kido et 
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al., 2009), liposomes (Barrett et al., 2006), gold particles (Alric et al., 2008), polymers 
(Caravan et al., 1999) and albumins (Ogan et al., 1987; Barrett et al., 2006; Yan et al, 
2006). 
A remarkable perspective in MRI provides the introduction of a tissue specific 
targeting moiety to the contrast agent. High local concentration of contrast enhancing 
material at a particular site within the human body enables precise medical diagnosis 
and will become an essential tool in tracking the progress of therapies. Currently, 
great effort is invested in the development of such tissue specific contrast agents. 
The concept of liver targeting is realized by the introduction of lipophilic moieties to 
the contrast agent or alternatively, the encapsulation of Gd-DTPA or Gd-DOTA 
chelates into liposomal nanoparticles (Weinmann et al., 2003). Development of MRI 
contrast agents with the capability of seeking out tumors is approached by different 
strategies. One proposal is the non-covalent interaction of contrast agents bearing 
charged residues with charged groups of polyornithine and polyarginine. It is known, 
that positively charged polyaminoacids selectively bind to tumors as their charge is 
more negative than non-tumor cells (Aime et al., 2000). Receptor targeting through 
monoclonal antibodies attached to contrast enhancing molecules is also widely 
investigated in this field of research. Monoclonal antibodies are an important category 
of targeting vectors and can be prepared to interact with a variety of receptor sites 
(Jaques and Desreux, 2002). Recently, the preparation and investigation of a peptide 
targeted contrast agent for molecular magnetic resonance imaging of fibronectin-
fibrin complexes in tumor tissues was published (Ye et al., 2008). The ability of 
imaging and diagnosing atherosclerotic plaques is of considerable interest since 
atherosclerotic diseases are among the leading causes of death in developed 
countries. Investigated methods to face the challenge of imaging fatty deposits 
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include the application of recombinant high density lipoprotein (HDL) like 
nanoparticles (Frias et al., 2004). Newly published investigations provide 
characterization of plaque in deep seated arteries using motexafin gadolinium 
(Brushett et al., 2008). MS 325, a gadolinium chelate that reversible binds to albumin 
in plasma has also been applied and areas of high signal intensity have been 
observed and were suggested not only to reflect the increased plaque vascularity but 
also the leakiness of the microvessels (Choudhury et al., 2002). In principle, also 
unspecific macromolecular or low molecular weight contrast agents suitable for 
imaging the blood pool bear the potential of indicating pathological alteration of the 
vasculature (Briley-Saebo et al., 2007).  
A targeting group capable of binding to endothelial cells is the tomato derived lectin 
LEA (Lycopersicon esculentum agglutinin) (Porter et al., 1990; Mazzetti et al., 2004). 
The attachment of this lectin to gadolinium loaded nanoparticles has already shown 
to provide contrast media with the ability of imaging the blood vessel walls in high 
spatial resolution (Paschkunova-Martic et al., 2005).  
Due to a considerably high number of functional groups albumin based nanoparticles 
represent promising systems for the development of MRI contrast enhancement and 
drug carriage facilities. Additionally, human serum albumin (HSA) derived 
nanospheres will be tolerated without side effects, since HSA is an integral 
component of plasma. The objective of this study was the preparation of Gd(III) 
loaded albumin-lectin nanoparticles for the exploration in targeted magnetic 
resonance imaging. For this purpose a bifunctional chelating agent was covalently 
attached to HSA and loaded with Gd(III). Different strategies were then explored to 
conjugate the modified albumin to LEA. Investigations of particle size and zeta 
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potential are also described. Finally, the relaxation behavior of the synthesized 
nanoparticles was evaluated. 
Materials and methods 
Chemicals and reagents 
Human serum albumin, Lectin (from Lycopersicon esculentum), phosphate buffered 
saline (1×PBS), glutaric dialdehyde (50 wt.% solution in water), glutaric anhydride as 
well as citric acid trisodium salt dihydrate and citric acid monohydrate for buffer 
preparation were purchased from Sigma-Aldrich. N-(3-dimethylaminopropyl)-N´-ethyl-
carbodiimide hydrochloride (EDC), 2-aminoethanol and sodium bicarbonate were 
obtained from Fluka. Ethanol (LiChrosolve®, gradient grade for liquid 
chromatography) was purchased from Merk. Trisodium bis(nitrilotriacetate)gadolinate 
solution (Na3[Gd(NTA)2]) (Paschkunova-Martic et al., 2005) as well as 2-(para-
aminobenzyl)-diethylenetriaminepentaacetic acid tetrahydrochloride (NH2-Bn-DTPA·4 
HCl) (Cummins et al., 1991) were prepared according to literature procedures. All 
water used was purified by a Millipore Synergy 185 UV Ultrapure Water System 
(Molsheim, France). 
Preparation of Gd(III) loaded human serum albumin 
Conjugation of the bifunctional chelating agent and subsequent complexation with 
Gd(III) was performed using a method described in a previous manuscript in this 
thesis (Kundu et al. 2009). HSA (53 mg, 0.8×10-3 mmol) was dissolved in 0.1 M 
NaHCO3 (10 ml) and cooled to 4°C. Glutaric anhydride (62 mg, 543.4×10-3 mmol) 
was added slowly in small portions while the pH of the mixture was maintained within 
a range of 7.8 - 8.2 by the addition of 0.6 M NaOH. Afterwards, the solution was 
stirred for 22 h at 4°C. To remove excess reagents the albumin-solution was 
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concentrated by centrifugation (Vivaspin 20, MWCO: 30000, 2500×g, 19°C) and 
washed with water (three times). The purified glutarylated albumin solution was 
diluted with H2O (7 ml) and NH2-Bn-DTPA•4HCl (60 mg, 931×10-3 mmol) in H2O (2 
ml) were added at ambient temperature. During the addition, the pH was repeatedly 
adjusted to 6.8 - 7.2 by 0.3 M NaOH. EDC (8 mg) was added and the conjugation 
reaction proceeded for 2 h at room temperature. To separate non-conjugated 
bifunctional ligand and low molecular weight compounds the solution was 
concentrated by centrifugation (Vivaspin 20, MWCO: 30000, 2500×g, 19°C) and 
again washed with water (three times). For the purpose of complexation with Gd(III) 
the modified albumin was then dissolved in 0.1 M citric buffer (10 ml) (pH 6.5) and 
cooled to 4°C. 0.1 M Gd(NTA)2 solution (2.5 ml, 0.25 mmol)  was added and allowed 
to react for 19 h. Finally, the reaction mixture was concentrated by centrifugation 
(Vivaspin 20, MWCO: 30000, 2500×g, 19°C) and washed with water (three times) to 
give a purified aqueous solution (10 mg/ml) of the gadolinium loaded HSA.  
 
Albumin determination 
The protein concentration of purified gadolinium loaded albumin solutions was 
determined by the method of Bradford. A Bradford test kit from Bio-Rad Laboratories 
(Vienna, Austria) was used and adapted for usage in 96 - well plates. Optical 
densities at 595 nm were recorded on a microplate reader (Synergy HT, Biotek) 15 
min. after the addition of Bradford solution. 
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Determination of the gadolinium content 
Gadolinium content of purified loaded albumin solutions was determined by an ICP-
MS (Inductively Coupled Plasma Mass Spectrometry) instrument (Agilent 7500ce, 
Waldbronn, Germany), equipped with a CETAC ASX-520 autosampler (Neuss, 
Germany), a Scott double pass spray chamber, and a MicroMist nebulizer.  
 
Preparation of Gd-HSA-Lectin nanoparticles by the activation of HSA (method 1) 
Gd-HSA solution (0.531 ml, 5.31 mg) was diluted in PBS (1 ml) and the pH was 
adjusted to 8 by the use of 0.01 M NaOH. Glutaraldehyde ((10 µl, 10% solution) was 
added and mixed by rotation (Multi Bio RS 24) for 5 h at 30 rpm. To remove excess 
glutaraldehyde the reaction liquid was concentrated by centrifugation (Vivaspin 20, 
MWCO: 30000, 2500×g, 19°C) and washed with water (three times). The activated 
Gd-albumin was diluted in PBS (3 ml) and LEA (2 mg) dissolved in H2O (0.4 ml) was 
added. After 18 h of rotation (Multi Bio RS 24) at 30 rpm the reaction was quenched 
by the addition of aminoethanol (20 µl) and the suspension was rotated for one 
further hour. The resulting nanoparticles were purified by centrifugation (Vivaspin 20, 
MWCO: 30000, 2500×g, 19°C) and redispersion in water (three times).  
 
Preparation of Gd-HSA-Lectin nanoparticles by desolvation (method 2) 
The nanoparticles were prepared using a modification of a previously described 
technique (Weber et al., 2000; Langer et al., 2003). Gd-HSA solution (0.53 ml, 5.31 
mg) was diluted in H2O (1 ml) and LEA (2 mg) dissolved in H2O (0.4 ml) was added. 
The pH was adjusted to 8.2 with 0.01 M NaOH. EtOH (1.6 ml) was added dropwise 
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(1 ml/min) under constant stirring (1000 rpm) at room temperature. Subsequently, 
glutaraldehyde (8 µl, 10% solution) was added to crosslink the protein molecules. 
The reaction proceeded for 22 h under stirring. Unconverted glutaraldehyde was 
inactivated by the addition of aminoethanol (20 µl) and the suspension was stirred for 
a further hour. The resulting nanoparticles were purified by centrifugation (Vivaspin 
20, MWCO: 30000, 2500×g, 19°C) and redispersion in water (three times). 
 
Preparation of Gd-HSA-Lectin nanoparticles by simultaneous crosslinking (method 3) 
At room temperature, Gd-HSA solution (0.53 ml, 5.31 mg) was diluted in H2O (1 ml) 
and LEA (2 mg) dissolved in H2O (0.4 ml) was added. The pH was adjusted to 8.2 
with 0.01 M NaOH. To start the crosslinking reaction glutaraldehyde (8 µl, 10% 
solution) was added and the reaction was allowed to proceed for 22 h. Excess 
glutaraldehyde was inactivated by the addition of aminoethanol (20 µl) and the 
suspension was stirred for a further hour. The resulting nanoparticles were purified by 
centrifugation (Vivaspin 20, MWCO: 30000, 2500×g, 19°C) and redispersion in water 
(three times). 
 
Preparation of Gd-HSA-Lectin nanoparticles by the activation of LEA (method 4) 
LEA (2.5 mg) dissolved in H2O (0.5 ml) was diluted in 0.1 M NaHCO3 (4 ml) and 
cooled to 4°C. Glutaric anhydride (15 mg) was added in small portions and the pH 
was maintained between 7.8 and 8.2 by the addition of 0.1 M NaOH. The 
glutarylation was allowed to proceed for 2 h at 4°C. Thereafter, repeated 
centrifugation (Vivaspin 20, MWCO: 30000, 2500×g, 19°C) and washing with water 
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removed small molecular weight compounds. The purified and concentrated 
glutarylated lectin solution was diluted with water (7 ml). Gd-HSA solution (0.7 ml, 7 
mg) was added and the pH was adjusted to 6.7 by 0.1 M HCl. EDC (5 mg) was 
added and the conjugation reaction proceeded for 1 h. During this time the pH was 
permanently corrected to 6.7. The resulting nanoparticles were purified by 
centrifugation (Vivaspin 20, MWCO: 30000, 2500×g, 19°C) and redispersion in water 
(three times). 
 
Measurement of particle size and zetapotential 
Particle size distribution of the undiluted sample was measured by dynamic light 
scattering (DLS) at a 173° angle using a Zetasizer Nano ZS (Malvern Instruments, 
UK). Each measurement consists of 5 runs of 20 sec. The temperature of the 
dispersant (ultrapure water) was set to 21 °C. We used low volume disposable sizing 
cuvettes made from poly methyl metacrylate.  
In a first step the measured autocorrelation function was analyzed by the cumulant 
method with quadratic weighing for the average particle size (z-average, first 
cumulant) and the polydispersivity (PDI, second cumulant). For particle size 
distribution analysis we used in addition the Malvern Instruments general purpose 
method, i.e. a fitting of the autocorrelation function to a set of logarithmic decay 
functions. We used the mode (i.e. the 1st peak of the intensity weighted distribution) 
for further data interpretation. Especially for broader particle size distributions with a 
higher polydispersivity the z-average determined by the cumulant anlysis differs from 
the mode determined by the general purpose method. 
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The electrophoretic mobility of the particles was measured by laser Doppler 
velocimetry with the same instrument. We used folded capillary cells and injected the 
undiluted samples with a syringe to prevent encapsulation of air bubbles. The 
Smoluchowski approximation (F(Ka) = 1.5) was used to calculate the zeta potential 
from electrophoretic mobility. We calculated average values and standard deviation 
out of three individual measurements. 
 
Spin-Lattice and Spin-Spin Relaxivity measurements 
Relaxivity measurements were performed on a 3 Tesla whole-body MRI scanner 
(TimTrio 3 T, Siemens Medical Solutions, Erlangen, Germany) using a whole body 
coil for excitation and standard head receiver coil for signal reception. Homogeneity 
of B1-field was insured by test measurements before the actual measurements of 
relaxivity. For each agent four dilutions ranging from 1.25 mg/ml to 10 mg/ml in PBS 
with the volume of 0.25 ml were prepared. All probes were measured in standard PE-
tubes with a diameter of 0.8 cm. The tubes were placed in the centre of a plastic box 
surrounded by water heated to 37°C. 
For the determination of spin-lattice relaxation times T1, spin echo inversion recovery 
(IR) sequences with inversion times from 0 to 3500 ms (TI = 0, 60, 80, 100, 150, 200, 
250, 300, 400, 500, 750, 1000, 1250, 1500, 1750, 2000, 2500, 3500 ms) were used. 
An adiabatic pulse was applied for B1 insensitive inversion. The other parameters 
were: TR/TE = 5000/8.1 ms; flip angle 180°; 8 turbo factor 11; FOV read 180 × 180 
mm; resolution matrix 192 × 192; bandwidth 260 Hz/pixel; and slice thickness 3 mm. 
The mean values of the signal intensities, the standard deviations, and pixel counts 
were determined by drawing regions of interest. The area assessed measured 
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between 0.12 cm2 and 0.14 cm2; for each measurement series, the measured area 
was kept identical by copying and pasting the ROI. For all measurements, the 
relaxation rates (R1) and the relaxivities (r1) were calculated for each substance. The 
longitudinal relaxation rate (R1) was calculated using the equation: 
 
SI (TI)= A[1-2 exp(-R1*TI)+exp(-R1*TR)] [1] 
 
with SI being the signal intensity as a function of TI, “A” accounting for the thermal 
equilibrium magnetization M0, and TI being the inversion time in ms.  
For the determination of individual spin-spin relaxation times (T2), spin-echo 
sequence with multiple echoes (NE= 5) ranging from 13.8 ms to 69 ms was used. 
Repetition time was set to 2500 ms, FOV 160 × 160 mm, resolution matrix 128 × 128, 
bandwidth 260 Hz/pixel; and slice thickness 3 mm. The mean values of the signal 
intensities, the standard deviations, and pixel counts were determined by drawing 
regions of interest. The area assessed measured between 0.12 cm2 and 0.14 cm2; 
for each measurement series, the measured area was kept identical by copying and 
pasting the ROI. For all measurements, the relaxation rates (R2) and the relaxivities 
(r2) were calculated for each substance. The transversal relaxation rates (R2) were 
calculated as the reciprocal value of the slope of semilogarithmic plot of signal 
intesities at individual echo times and respective echo times. 
The relaxivities (r1, r2) were calculated as the slope of linear regression of R1 and R2 
as a function of contrast agent concentration. 
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Results and Discussion 
The objective of this study was the evaluation of different parameters to characterize 
the prepared nanoparticles with regard to a possible application in MRI.  
The synthesis of Gd(III) loaded human serum albumin is based on a technique 
described in a previous manuscript in this thesis (Kundu et al., 2009). The 
bifunctional chelating agent NH2-Bn-DTPA was covalently attached to the albumin by 
a glutaric acid linker. Amide coupling to the primary amine functionalities of lysine 
residues as well as amide formation to the primary amine of the ligand provided 
stable conjugation. Gadolinium coordination exclusively to the DTPA derivative 
succeeded by the introduction of a Gd(NTA)2 solution. Nitrilotriacetic acid was utilized 
for the reason of being a weak ligand for Gd(III) and therefore, to prevent nonspecific 
complexation to proteins which may result in the release of free Gd(III) (Spanoghe et 
al., 1992). The gadolinium:albumin ratio was determined by the measurement of 
protein concentration by the Bradford assay and the determination of the metal 
content by ICP-MS. The detected gadolinium amount was related to the protein 
concentration and indicated that 35 contrast enhancing Gd(III) ions were attached to 
each albumin molecule (Figure 1). 
Syntheses of nanoparticles were performed by four different strategies to indicate 
possible variations in size, zeta potential and relaxivity behavior. The 
homobifunctional reagent glutaraldehyde was chosen as crosscoupling reagent due 
to its convenient handling. The use of this probably most popular protein crosslinking 
reagent is well established in literature (Hermanson, 2008). After the reaction, 
remaining aldehyde functionalities were inactivated by the addition of aminoethanol. 
This procedure prevented further crosscoupling. Applied techniques covered the 
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activation of Gd-HSA with glutaric dialdehyde followed by subsequent addition of the 
lectin for conjugation (method 1). Furthermore, a preparation method utilizing a 
modification of a previously described desolvation technique (Weber et al., 2000; 
Langer et al., 2003) has been investigated (method 2). The simultaneous crosslinking 
of Gd-HSA and LEA by glutaraldehyde was examined as well (method 3). Finally, the 
crosslinking of Gd-HSA and LEA with prior activation of the lectin by glutaric 
anhydride has been performed (method 4). The choice of employing glutaric 
anhydride was made to evaluate possible differences in size or size distribution in 
contrast to nanoparticles derived from glutaraldehyde crosslinking. 
The particle size distribution of nanoparticles prepared by all four methods show 
multiple peaks. The first peak is mostly attributable to unconverted starting material 
(at around 10 nm). None of the methods described did completely polymerize the 
provided Gd-HSA and lectin molecules. A discrimination of Gd-HSA and LEA by PCS 
is not possible as both have almost the same size. The high intensities of 
unpolymerized material do not necessarily indicate a higher amount of not 
conjugated proteins in comparison to crosslinked nanoparticles. The second peak 
indicates the polymerized Gd-loaded nanoparticles. Method 4 produced the smallest 
particles (112 nm) compared to the other methods (186 to 304 nm). This might be a 
consequence of the applied method of synthesis. Primary activation of LEA and 
subsequent conjugation to Gd-HSA through a glutaric acid linker give well defined 
structures of nanoparticles. This is also indicated by the low PDI (0.19). In contrast, 
preparation method 1-3 – conjugated by glutaraldehyde linkage - form Gd-HSA-LEA 
conjugates having increased size and a less narrow size distribution and higher PDI, 
indicating the heterogeneity of the sample (see also Table 1). These differences can 
possibly be explained by the distinct properties of the linkers. Glutaric acid, bearing 
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two acid functionalities, connects two macromolecules. Whereas, it is known that 
glutaraldehyde forms α,β - unsaturated polymers in aqueous solutions which are 
highly reactive towards primary amines. The polymer size and structure is unknown 
and may be influenced by the age of the glutaraldehyde solution (Hermanson, 2008). 
As the glutaraldehyde polymer provides more than just two reactive functionalities 
per molecule, it promotes further crosslinking leading to a broader distribution of 
formed nanoparticles. However, method 4 also shows a distinct peak at 463 nm 
which can be interpreted as a temporary reversible aggregation. Peaks above 1 µm 
can be interpreted as remnants of the autocorrelation fitting algorithm or, although 
unlikely, as contamination through dust.  
The ability of the Gd-HSA-LEA conjugates to modify the relaxation rate of water was 
evaluated at 37°C in PBS. Relaxation rates (R1, R2) and respective relaxivities (r1, r2) 
were measured at 3T and are displayed in Table 2. As the accurate structure and 
molecular weight of the tomatoe lectin is still unclear (Oguri et al., 2008), the 
molecular weight of the prepared nanoparticles is hardly to determine. For that 
reason the relaxation rates and the relaxivities are given related to the amount of 
substance in mg. Two effects account for the differences in relaxivity. First, 
accessibility of the gadolinium ion for protons within the Gd-HSA-LEA conjugates 
prepared by diverse techniques and secondly, the variations in the tumbling rate of 
the nanoparticles. These properties impact the water exchange rate and hence, the 
relaxivity of the particles. 
In conclusion, Gd-HSA-LEA nanoparticles were prepared by four different strategies. 
Particle size measurement indicated a range between 112 and 304 nm depending on 
the preparation method. Additionally, the relaxation behavior was evaluated. In effort 
to develop contrast agents with the capability of targeting the vasculature, further 
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investigations on the in vivo behavior like chelate stability, the degradability and the 
accumulation of these contrast enhancing conjugates at endothelial cells are 
required. 
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Figures and Tables 
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Figure 1. Gd(III) loaded HSA. 
 
 
 
Figure 2. Particle size distribution (nm) by intensity (%) for nanoparticle synthesis method 1 to 4 as 
well as the range for Lectin (grey bar). 
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Table 1. Detailed characterization of synthesized nanoparticles by dynamic light scattering (n=3, ± 
1SD).  
 
z-average 
(nm) 
peak 1 (nm) 
± 1SD 
peak 2 (nm) 
± 1SD 
peak 3 (nm) 
± 1SD 
PDI 
Count rate 
(kcps) 
Zeta potential 
(mV) ± 1SD 
Method 1 11.8 11.8 ± 3.82 304 ± 172.6 - 0.61 114.9 -0.69 ± 0.03 
Method 2 12.2 13.5 ± 4.79 186 ± 90.10 4090 ± 53 0.59 144.4 -0.32 ± 0.19 
Method 3 13.6 14.0 ± 5.02 239 ± 121.3 - 0.65 185.9 -2.39 ± 0.36 
Method 4 95.9 11.6 ± 2.88 112 ± 33.6 463 ± 162.2 0.19 151.8 1.24 ± 0.4 
LEA 1842.0 15.7 ± 1.50 - - 1.00 387.8 - 
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Table 2. Relaxation behavior of the nanoparticles 
Method cconjugate(mg/ml) R1(s-1) r1[s-1*(mg/ml)-1] R2(s-1) r2[s-1*(mg/ml)-1] 
Method 1 
10 2.414 0.166 4.097 0.284 
5 1.669  2.989  
2.5 1.389  2.350  
1.25 0.826  1.389  
Method 2 
10 4.108 0.354 8.130 0.686 
5 /  /  
2.5 1.591  3.210  
1.25 1.047  1.980  
Method 3 
10 3.688 0.294 7.515 0.607 
5 3.044  6.295  
2.5 1.699  3.431  
1.25 1.053  2.964  
Method 4 
10 4.902 0.445 11.336 1.023 
5 3.032  7.307  
2.5 1.680  4.082  
1.25 0.972  2.21  
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